Fig. 4

The anti-fibrotic effect of Agomir-122@MNP on activated CDFs. A TGFBR2 expression of inactivated CDFs and activated CDFs with different interventions, as indicated by western blot. B Quantification of TGFBR2 expression. C Col 1 and α-SMA expression of inactivated CDFs and activated CDFs with different interventions, as indicated by western blot. D Quantification of Col 1 and α-SMA expression. E Cell activity of inactivated CDFs and activated CDFs with different interventions, as indicated by CCK-8 assay. F Cell viability of inactivated CDFs and activated CDFs with different interventions, as indicated by BrdU staining (green). G Quantification of BrdU staining. H Cell contraction ability of inactivated CDFs and activated CDFs with different interventions, as indicated by collagen gel contraction assay (red circle indicated the collagen gel). I Quantification of collagen gel area. Scale bar: 200 μm. (n = 3). *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001. I: Unactivated CDFs, II: Activated CDFs, III: Agomir-122 + activated CDFs, IV:Agomir-122@NP + activated CDFs, V: Agomir-122@MNP + activated CDFs